Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Initial search results include only NCI-sponsored clinical trials. To search all trials, click the "REFINE SEARCH" button, scroll down to the Trial ID/Sponsor section and select the "All" check box in the Sponsor of Trial section.

View Content for:
Display:
?
Drug:  vatalanib
Find trials that include:  Any drugs shown
Trial Status:  Closed
Results 1-25 of 25 for your search:
Start Over
Study of Oxaliplatin/5-FU/Leucovorin Plus Vatalanib Versus Oxaliplatin/5-FU/Leucovorin in Patients With Metastatic Colorectal Cancer.
Phase: Phase III
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CPTK787 0135/306241, CONFIRM 1, NCT00056459
PTK 787 and Gleevec in Patients With AML, AMM, and CML-BP
Phase: Phase II, Phase I
Type: Treatment
Status: Completed
Age: 15 and over
Sponsor: Other
Protocol IDs: 2004-0248, NCT00088231
Temozolomide and Radiation Therapy With or Without Vatalanib in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
Phase: Phase II, Phase I
Type: Treatment
Status: Completed
Age: 18 to 69
Sponsor: Other
Protocol IDs: EORTC-26041-22041, EORTC-26041, EORTC-22041, EUDRACT-2004-003896-35, NCT00128700
Phase 1-2 Vatalanib and Gemcitabine in Advanced Pancreatic Cancer
Phase: Phase II, Phase I
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: IRB-06999, 95533, CPTK787AUS08, PANC0002, NCT00185588
Study of the Safety, Tolerability, Pharmacokinetics, and Anti-tumor Effects of Vatalanib in Combination With Capecitabine in Patients With Advanced Cancer
Phase: Phase II, Phase I
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CPTK787 0134/306220, NCT00171587
PTK/ZK in Disseminated Malignant Melanoma
Phase: Phase II, Phase I
Type: Treatment
Status: Temporarily closed
Age: 18 and over
Sponsor: Other
Protocol IDs: UKSH A-105, EudraCT No. 2005-002192-32, NCT00615160
PTK787/ZK 222584 in Treating Patients With Unresectable Malignant Mesothelioma
Phase: Phase II
Type: Treatment
Status: Completed
Age: Over 18
Sponsor: NCI, Other
Protocol IDs: CDR0000269537, U10CA031946, CALGB-30107, NCT00053885
Vatalanib in Treating Patients With Primary or Secondary Myelodysplastic Syndromes
Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: CDR0000339810, U10CA031946, CALGB-10105, NCT00072475
Study of PTK787 in the Treatment of Patients With Non-Metastatic Androgen Independent Prostate Cancer
Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Other
Protocol IDs: UMCC 2005.014, NCT00134355
Protein Tyrosine Kinases (PTK) in Multiple Myeloma
Phase: Phase II
Type: Treatment
Status: Completed
Age: over 18
Sponsor: Other
Protocol IDs: 03-257, NCT00165347
Safety and Efficacy Study of a New Chemotherapy Agent to Treat Non Small Cell Lung Cancer.
Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 91411, 2004-002290-22, 308801, NCT00160043
PTK787 in Patients With Advanced Metastatic Pancreatic Adenocarcinoma
Phase: Phase II
Type: Treatment
Status: Completed
Age: over 18
Sponsor: Other
Protocol IDs: PCRT04-001, NCT00226005
PTK787/ZK222584 in the Treatment of Metastatic Gastrointestinal Stromal Tumors Resistant to Imatinib
Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Other
Protocol IDs: CPTK787 A2401/300267, GIST PTK787/ZK222584, NCT00117299
Vatalanib in Treating Patients With Recurrent or Progressive Meningioma
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Completed
Age: 18 and over
Sponsor: Other
Protocol IDs: NU 05C4, STU00005338, NU-1398-025, NOVARTIS-NU-05C4, NCT00348790
Phase II Study of Vatalanib in Patients With Unresectable Metastatic Cutaneous Melanoma. Note: The information about this trial has not been updated by the sponsor/principal investigator/lead organization. Cancer.gov cannot verify the accuracy of the information.
Phase: Phase II
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Other
Protocol IDs: CRCA-CCTC-CAMEL02, EU-20787, EUDRACT-2005-004710-33, CCTC-Camel-02, CCLG-Camel-02, ISRCTN191981, NCT00563823
The Safety and Efficacy of CPTK787/ZK222584 in Patients With Metastatic Neuroendocrine Tumors
Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Other
Protocol IDs: CPTK787/ZK222584, NCT00627198
Phase I Study of PTK787/ZK 222584 in Patients With HIV-Associated Kaposi's Sarcoma (Summary Last Modified 01/2000)
Phase: Phase I
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: NCI, Pharmaceutical / Industry
Protocol IDs: AMC-016, NOVARTIS-CPTK7870104
Warfarin and Vatalanib in Treating Patients With Advanced Solid Tumors
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: CDR0000386239, P30CA016042, UCLA-0403067-01, NOVARTIS-CPTK7870113, NCT00091299
Vatalanib and Everolimus in Treating Patients With Advanced Solid Tumors
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: Pro00012347, DUMC-6626-04-12R0, CDR0000454988, NCT00303732
Docetaxel and PTK787 in Metastatic Breast Cancer Patients and Gynecological Cancer Patients
Phase: Phase I
Type: Treatment
Status: Completed
Age: Over 18
Sponsor: Other
Protocol IDs: 05-020, NCT00268918
Imatinib Mesylate, Vatalanib, and Hydroxyurea in Treating Patients With Recurrent or Relapsed Malignant Glioma
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: Pro00006014, DUMC-7019-06-3R1, NOVARTIS-DUMC-7019-06-3R1, NCT00387933
Trial of PTK787/ZK 222584 Plus Paclitaxel
Phase: Phase I
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Other
Protocol IDs: 05-046, NCT00358163
Vatalanib and Pemetrexed Disodium in Treating Patients With Advanced Solid Tumors
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Temporarily closed
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: MC0515, NCI-2009-01316, P30CA015083, MAYO-MC0515, MAYO-06-002065, NOVARTIS-CPTK787AUS16, NCT00390000
PTK787/ZK 222584 in Combination With Temozolomide and Radiation in Patients With Glioblastoma Taking Enzyme-Inducing Anti-Epileptic Drugs
Phase: Phase I
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Other
Protocol IDs: 06-013, NCT00385853
Everolimus and Vatalanib in Treating Patients With Advanced Solid Tumors
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Closed
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: MC0414, NCI-2009-01200, P30CA015083, MAYO-MC0414, NCT00655655
Start Over